Financial Performance - Operating revenue for Q1 2022 was CNY 3,474,903.37, representing a significant decline of 65.75% year-over-year due to COVID-19 impacts[16] - The net profit attributable to shareholders for Q1 2022 was a loss of CNY 5,403,616.84, a decrease of 384.09% compared to the same period last year[14] - The basic earnings per share for Q1 2022 was -CNY 0.08, down 300.00% from -CNY 0.02 in Q1 2021[14] - The total comprehensive loss for Q1 2022 was CNY -5,536,327.48, compared to CNY -1,189,168.53 in Q1 2021[55] - Total operating costs for Q1 2022 were CNY 10,802,812.75, down from CNY 14,808,765.24 in Q1 2021[53] - Net loss for Q1 2022 was CNY -5,536,327.48, compared to a net loss of CNY -1,189,168.53 in Q1 2021[55] - Other income for Q1 2022 was CNY 2,123,770.49, down from CNY 3,006,062.66 in Q1 2021[54] Cash Flow - The net cash flow from operating activities for Q1 2022 improved by 23.58%, amounting to -CNY 11,192,319.89 compared to -CNY 14,644,951.67 in the previous year[14] - Operating cash flow for Q1 2022 was negative at -11,192,319.89 yuan, compared to -14,644,951.67 yuan in Q1 2021, indicating an improvement of approximately 23.5% year-over-year[59] - Total cash inflow from operating activities was 8,384,786.97 yuan in Q1 2022, down from 16,813,319.46 yuan in Q1 2021, representing a decline of about 50%[59] - Cash outflow from operating activities totaled 19,577,106.86 yuan in Q1 2022, compared to 31,458,271.13 yuan in Q1 2021, showing a reduction of approximately 37.9%[59] - The net cash flow from financing activities was -426,927.38 yuan in Q1 2022, compared to a positive inflow of 13,043,475.00 yuan in Q1 2021[60] - The company reported a cash and cash equivalents balance of 82,949,508.81 yuan at the end of Q1 2022, down from 124,980,991.13 yuan at the end of Q1 2021[60] Assets and Liabilities - The total assets as of March 31, 2022, were CNY 259,612,846.78, a decrease of 2.08% compared to the end of the previous year[14] - The company's total equity attributable to shareholders decreased by 2.12% to CNY 249,100,149.53 as of March 31, 2022[14] - Total liabilities decreased to CNY 7,941,559.90 in Q1 2022 from CNY 9,746,735.77 in the previous year[51] - The total equity decreased to CNY 251,745,220.68 in Q1 2022 from CNY 256,809,847.90 in Q1 2021[51] - The total assets with restricted rights amount to CNY 340,780, representing 0.13% of total assets, related to a performance guarantee for a project[41] Shareholder Information - The number of ordinary shareholders as of the report date was 6,779[21] - The largest shareholder, Xu Yifan, holds 27,111,273 shares, representing 40.85% of total shares[22] - The second largest shareholder, Dongyuan Qihua, holds 2,712,000 shares, accounting for 4.09%[22] - The total shares held by the top ten shareholders amount to 40,109,823, which is 60.44% of the total[24] Commitments and Compliance - The company has ongoing commitments to avoid competition with its actual controllers and shareholders, initiated in January 2016, and is currently fulfilling these commitments[28] - The company has made commitments to reduce related party transactions, also initiated in January 2016, and is actively fulfilling these commitments[29] - The company has a commitment not to occupy company funds or assets, which started in January 2016, and is currently being fulfilled[29] - The company has a commitment regarding tax payment issues, ensuring personal liability for any losses incurred by the company due to tax withholding problems, initiated in January 2016, and is currently fulfilling this commitment[29] - The company has a lock-up commitment for shares issued on December 8, 2020, which is currently being fulfilled[30] - The company has commitments regarding share reduction intentions, initiated on December 8, 2020, and is actively fulfilling these commitments[30] - The company has a commitment to maintain stock price stability for three years after listing on the selected layer, initiated on December 8, 2020, and is currently fulfilling this commitment[30] - The company is committed to ensuring that there are no false records or misleading statements in the public offering documents[32] - The company acknowledges its legal responsibility for the accuracy and completeness of the public offering documents[32] - The company is committed to maintaining transparency and accountability in its financial disclosures[32] Legal and Regulatory Matters - There were no significant legal disputes or external guarantees reported during the period[27] - The company has not engaged in any major asset acquisitions or disposals during the reporting period[27] - There were no penalties or investigations reported against the company[27] - There are no overdue commitments or violations of promises made by the company during the reporting period[39] - The company has not undergone any asset seizures, freezes, or pledges during the reporting period[40]

Product Development and Innovation - The "High-definition Digital Human Virtual Anatomy Platform System" and "Digital Human High-definition 3D Printing Model" were recognized as reaching international advanced and leading levels respectively by experts from the Chinese Anatomical Society[7]. - The "Intelligent Cardiopulmonary Resuscitation Training System" was evaluated as reaching domestic leading level, addressing existing product deficiencies in the market[7]. - The company emphasizes the importance of continuous technological innovation and product upgrades to maintain its competitive edge in the digital medical software market[15]. - The company continues to increase investment in technology research and development, focusing on key technologies such as digital human technology, image recognition, and data processing[57]. - The company has established a research center and a digital human research institute to enhance its R&D capabilities, focusing on high-precision digital human products for clinical diagnosis and sports anatomy[58]. - The company plans to enhance its product offerings in the digital human technology sector, leveraging its established database and research capabilities[66]. - The company aims to strengthen its market presence in the medical education sector by optimizing its technology structure and enhancing product quality to improve core competitiveness[59]. - The company has established partnerships with over 400 medical institutions and has developed 13 invention patents and 62 copyrights[50]. Financial Performance - The company's operating revenue for 2021 was ¥83,717,513.88, a decrease of 16.77% compared to ¥100,583,059.71 in 2020[33]. - The net profit attributable to shareholders for 2021 was ¥15,939,794.48, down 45.17% from ¥29,070,135.08 in 2020[33]. - The gross profit margin for 2021 was 60.82%, a decline from 64.90% in 2020[33]. - The company's cash flow from operating activities for 2021 was ¥28,193,946.82, representing a significant increase of 1,008.92% compared to ¥2,542,478.16 in 2020[37]. - The company's total revenue for digital medical products reached ¥28,977,173.52, with a gross margin of 77.06%, reflecting a decrease of 24.53% compared to the same period last year[75]. - The revenue from clinical digital anatomy system solutions was ¥19,886,024.80, showing a significant increase of 66.70% year-on-year, although the gross margin decreased by 15.11% due to rising costs[79]. - The company reported a net loss of RMB 909,684.83 from its subsidiary, Shenzhen Yichuang Hongtu Technology Co., Ltd.[96]. - The company reported a total revenue of RMB 83,717,513.88 in 2021, with digital medical products contributing RMB 81,881,660.64, accounting for 97.81% of total revenue[107]. Market and Competition - Increased market competition is anticipated as the medical informationization industry accelerates, posing a risk to revenue growth if the company fails to meet evolving customer needs[14]. - The company faces risks from potential changes in national policies that could adversely affect the medical informationization industry[14]. - The company recognizes the urgent demand for medical education due to the talent gap exacerbated by the COVID-19 pandemic, providing a substantial growth opportunity in the medical education market[64]. - The digital medical education market is projected to have substantial growth potential, with over 700 medical colleges in China undergoing digital transformation[51]. - The company is focused on addressing the challenges in medical education, including resource shortages and imbalances in training across regions[123]. Governance and Risk Management - The company has established a sound corporate governance structure since its transformation into a joint-stock company in 2015[16]. - The actual controller, Xu Yifa, directly and indirectly controls 41.71% of the shares, which poses a risk of potential conflicts of interest[17]. - The company has established key internal controls related to revenue recognition to mitigate risks associated with inappropriate revenue reporting[108]. - The company emphasizes the importance of internal control and risk prevention to ensure long-term sustainable development[61]. - The company has made commitments regarding stock repurchase plans and maintaining stock price stability following its public offering[154]. Research and Development - The company invested CNY 20.82 million in R&D in 2021, accounting for 24.87% of its operating revenue[15]. - The company’s R&D team consists of over 100 members, ensuring technological leadership in the industry[51]. - The total number of R&D personnel decreased from 142 to 140, while the proportion of R&D personnel to total employees increased from 61.14% to 62.56%[103]. - The company has committed to enhancing medical education and providing high-quality products and services to improve healthcare standards[117]. Regulatory Environment - The company operates in a supportive regulatory environment for the healthcare information technology sector, which may change and impact future operations[18]. - The national policy encourages the development of educational information technology, aiming for comprehensive coverage of digital applications in education by 2022[121]. - The company is committed to timely tracking policy changes and adapting its strategies to maintain a competitive edge in the market[133]. Employee Management - The company adheres to the principle of "people-oriented," ensuring good compensation, benefits, and a supportive work environment for employees[117]. - The total number of employees increased from 227 to 229, with a net addition of 5 employees during the period[199]. - The number of master's degree holders among employees increased from 11 to 12[200]. - The company’s management compensation is based on a structured salary system including various components such as position salary and year-end bonuses[197]. Financial Management - The company is committed to improving its financial management system to enhance the quality of accounting information and support decision-making processes[61]. - The company has a performance guarantee deposit of 340,780.00 yuan, accounting for 0.13% of total assets, with no adverse impact on the company[164]. - The company has confirmed that there were no violations of commitments regarding competition during the reporting period, maintaining compliance with regulations[158].

证券代码：835670 证券简称：数字人 公告编号：2021-072 山东数字人科技股份有限公司 关于接待机构投资者调研情况的公告 | --- | |------------------------------------------------------------------------| | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 | | 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 | | 带法律责任。 | 山东数字人科技股份有限公司（以下简称"公司"）于 2021 年 12 月 23 日 接待了 41 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2021 年 12 月 23 日 调研地点：山东数字人科技股份有限公司会议室 调研形式：网络调研 调研机构：南方基金、华夏基金、国寿安保、财通基金、毅达资本、北京洪 泰同创投资管理有限公司、东源华信（北京）资本管理有限公司、米琳资本、淄 博国基新材料产业创业投资有限公司、淄博齐鲁创业投资有限责任公司、中航产 业投资有限公司、青岛晨鸣资产管理有限公司、星辰民航基金、合利投资、 ...